Xu, R., Muro, K., Morita, S., Iwasa, S., Han, S. W., Wang, W., . . . Kim, T. W. (2018). Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): A multicentre, open-label, randomised, non-inferiority, phase 3 trial. The Lancet Oncology, 19(5), 660-671. https://doi.org/10.1016/S1470-2045(18)30140-2

Xu, Rui-Hua, et al. "Modified XELIRI (capecitabine Plus Irinotecan) Versus FOLFIRI (leucovorin, Fluorouracil, and Irinotecan), Both Either with or Without Bevacizumab, as Second-line Therapy for Metastatic Colorectal Cancer (AXEPT): A Multicentre, Open-label, Randomised, Non-inferiority, Phase 3 Trial." The Lancet Oncology 19, no. 5 (2018): 660-671. https://doi.org/10.1016/S1470-2045(18)30140-2.

Xu, Rui-Hua, et al. "Modified XELIRI (capecitabine Plus Irinotecan) Versus FOLFIRI (leucovorin, Fluorouracil, and Irinotecan), Both Either with or Without Bevacizumab, as Second-line Therapy for Metastatic Colorectal Cancer (AXEPT): A Multicentre, Open-label, Randomised, Non-inferiority, Phase 3 Trial." The Lancet Oncology, vol. 19, no. 5, 2018, pp. 660-671, https://doi.org/10.1016/S1470-2045(18)30140-2.